Levothyroxine suppressive therapy for solitary thyroid nodule
Levothyroxine suppressive therapy for solitary thyroid nodule
复制标题
DOI：
10.1007/bf03349813
复制
发表时间：
1995-11-01
影响因子：
5.4
通讯作者：
Mazzi, C
中科院分区：
文献类型：
--
作者：
Mainini, E;Martinelli, I;Mazzi, C
为了评价TSH抑制剂量的左旋甲状腺素减少单个甲状腺结节体积的效果，我们研究了55名甲状腺功能正常的患者：45名（A组）患者用LT（4）（平均1.7 ± 0.9 μ g/Kg/天）抑制21.3 ± 5.3个月，10名患者（B组）作为对照。所有结节在CT扫描时均为“冷”结节，超声检查为实性结节，细针穿刺细胞学检查为良性结节。作为应答者，假定结节在治疗结束时体积缩小50%。在研究开始和结束时评价甲状腺功能值（TSH、T-4、FT 4、T-3、FT 3、甲状腺过氧化物酶和甲状腺球蛋白抗体）、临床和超声检查结果。治疗组8例（17.8%）结节体积显著减少，而抑制组37例（82.2%）结节体积显著减少，所有对照组均无变化（A vs B=NS）。在两个未经治疗的患者中发现了新的结节;在治疗组中没有发现新的结节（A vs B p
In order to evaluate the efficacy of a TSH supressive dose of levothyroxine to reduce the volume of a single thyroid nodule we studied 55 euthyroid patient: 45 (group A) were suppressed with LT(4) (mean 1.7+/-0.9 mu g/Kg/day) for 21.3+/-5.3 months, and 10 patients (group B) served as controls. All the nodules were ''cold'' at scintiscanning, solid at ultrasonography and benign by fine-needle aspiration cytology. As responders were assumed the nodules shrinked at the end of treatment of 50% in volume. Thyroid function values (TSH, T-4, FT4, T-3, FT3, thyroid peroxidase and thyroglobulin antibodies), clinical and ultrasonographic findings were evaluated initially and at the end of the study. A significant nodular volume decrease occurred in 8 treated patients (17.8%) while 37 (82.2%) amongst the group suppressed and all controls showed no change (A vs B=NS). In two untreated patients new nodules were noted; no new nodules were discovered in the treated group (A vs B p